AKT1 and Familial prostate cancer: We demonstrated that ELOLV5-mediated polyunsaturated fatty acids (PUFAs) upregulation and the lipid raft-derived activation of AKT-mTOR pathway drives the therapy resistance and neuroendocrine differentiation (NED) of prostate cancer.